Assessment of KAN-101 in Celiac Disease (ACeD)

Study Purpose

A safety study of KAN-101 in patients with celiac disease. The study has two parts: 1. Part A

  • - first in human study in which patients receive a single dose of KAN-101.
2. Part B - patients will receive three doses of either KAN-101 or placebo

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.

Searching Both is inclusive of interventional and observational studies.

Eligible Ages 18 Years - 70 Years
Gender All
More Inclusion & Exclusion Criteria


Inclusion Criteria:

1. Adults aged 18 to 70 years inclusive. 2. Diagnosed with celiac disease based on positive serology (eg, tissue transglutaminase IgA antibody and/or deamidated gliadin peptide IgG) and intestinal histology consistent with ≥ Marsh Type II or with evidence of villous atrophy. 3. Has HLA-DQ2.5 genotype (HLA-DQA1*05 and HLA-DQB1*02) (homozygotes or heterozygotes) 4. Has followed a GFD for > 12 months immediately prior to study entry. 5. Negative or weak positive for tTG-IgA and negative or weak positive for DGP-IgA/IgG during screening. 6. Male or female. Females of childbearing potential must use at least 2 acceptable birth control methods. 7. Capable of understanding and complying with protocol requirements. 8. Patient understands and has signed the informed consent form. Key

Exclusion Criteria:

1. Refractory celiac disease. 2. Selective IgA deficiency. 3. Positive for HLA-DQ8 (DQA1*03, DQB1*0302) 4. Previous treatment with tolerance-inducing therapies for celiac disease. 5. Known wheat allergy. 6. Part B only: History of hyperacute or prolonged symptoms following gluten exposure. 7. Uncontrolled or significant medical conditions (including active infections or chronic hepatitis) which, in the opinion of the Investigator, preclude participation. 8. History of dermatitis herpetiformis. 9. Pregnant or breastfeeding

Trial Details

Trial ID:

This trial id was obtained from, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.


Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Overall Status Recruiting
Countries United States

The disease, disorder, syndrome, illness, or injury that is being studied.

Celiac Disease
Additional Details

Study KAN-101-01 is a Phase 1, FIH study designed to evaluate the safety and tolerability of KAN-101 in patients with celiac disease on a gluten free diet (GFD). An overview of the two parts and proposed dose groups is given below: 1. Part A (SAD): Patients will receive a single dose of KAN-101. 2. Part B (MAD): Patients will receive three doses of either KAN-101 or placebo.

Arms & Interventions


Experimental: SAD Cohort 1

All enrolled patients will receive one dose of KAN-101 Dose A

Experimental: SAD Cohort 2

All enrolled patients will receive one dose of KAN-101 Dose B

Experimental: SAD Cohort 3

All enrolled patients will receive one dose of KAN-101 Dose C

Experimental: SAD Cohort 4

All enrolled patients will receive one dose of KAN-101 Dose D

Experimental: MAD Cohort 5

All randomized patients will receive 3 doses of either KAN-101 Dose A or placebo

Experimental: MAD Cohort 6

All randomized patients will receive 3 doses of either KAN-101 Dose B or placebo

Experimental: MAD Cohort 7

All randomized patients will receive 3 doses of either KAN-101 Dose C or placebo


Drug: - KAN-101

Intravenous (IV) infusion

Drug: - Placebo

Intravenous (IV) infusion

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Anaheim Clinical Trials, Anaheim, California




Anaheim Clinical Trials

Anaheim, California, 92801

Site Contact

Hee Sung Ko

714-774-7777 #1089

Diablo Clinical Research, Walnut Creek, California




Diablo Clinical Research

Walnut Creek, California, 94598

Site Contact

Caitlin Sheets


GCP Research, Saint Petersburg, Florida




GCP Research

Saint Petersburg, Florida, 33705

Site Contact

Darryl Rosebud


Tandem Clinical Research, Marrero, Louisiana




Tandem Clinical Research

Marrero, Louisiana, 70072

Site Contact

Tim Flanary

+1 857-320-6607

Parexel International- EPCU Baltimore, Baltimore, Maryland




Parexel International- EPCU Baltimore

Baltimore, Maryland, 21225

West Michigan Clinical Research Center, Wyoming, Michigan




West Michigan Clinical Research Center

Wyoming, Michigan, 49519

Site Contact

Kayla Hinson


Mayo Clinic, Rochester, Minnesota




Mayo Clinic

Rochester, Minnesota, 55905

Site Contact

Carol Van Dyke


New York, New York




Celiac Disease Center at Columbia University

New York, New York, 10032

Site Contact

Benjamin Lebwohl, MD


North Carolina Clinical Research, Raleigh, North Carolina




North Carolina Clinical Research

Raleigh, North Carolina, 27607

Site Contact

Patty Becherer

+1 857-320-6607

Aventiv Research, Columbus, Ohio




Aventiv Research

Columbus, Ohio, 43213

Site Contact

Jessica Spear

614-501-6164 #2007

Advanced Clinical Research, West Jordan, Utah




Advanced Clinical Research

West Jordan, Utah, 84088

Site Contact

Ben Rigby


The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

PO Box 544, Ambler, PA 19002

Phone: 215-325-1306

Toll-Free: 844-856-6692

Press Room / Media Inquiries

Contact Information

The information found on this website is not intended to be a replacement or substitute for professional medical treatment or for professional medical advice relative to a specific medical condition. We urge you to always seek the advice of your physician. There is no replacement for personal medical treatment and advice from your personal physician.